ArticlePediatrics2018
Adoption of Serogroup B Meningococcal Vaccine Recommendations.
Article in Pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- A systematic review of demographic and socioeconomic characteristics associated with inequalities in invasive meningococcal disease prevention in high-income countries and Latin America.Human vaccines & immunotherapeutics · 2025Pooled it
- Inequalities in the risk and prevention of invasive meningococcal disease in the United States - A systematic literature review.Human vaccines & immunotherapeutics · 2024Pooled it
- Burden of Invasive Meningococcal Disease: Evolving Epidemiology and Implications for Prevention Policy.Infectious diseases and therapy · 2026Review
- Preventing Meningococcal Disease in US Adolescents and Young Adults Through Vaccination.Infectious diseases and therapy · 2025Review
- Context factors in clinical decision-making: a scoping review.BMC medical informatics and decision making · 2025Article
- Determinants of Meningococcal Vaccination Coverage and Adherence: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit.Infectious diseases and therapy · 2023Review
- Understanding the Factors Influencing Health Care Provider Recommendations about Adolescent Vaccines: A Proposed Framework.Journal of behavioral medicine · 2023Article
- Review
- Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review.Infectious diseases and therapy · 2022Review
- Outcomes from the Use of Targeted Interventions to Increase Meningococcal Vaccination Rates in a Pediatric Clinic.Journal of community health · 2022Article
- Factors Associated With Receipt of Meningococcal B Vaccine Among United States Adolescents, National Immunization Survey-Teen, 2017-2018.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2021Article
- Perceptions and Knowledge About the MenB Vaccine Among Parents of High School Students.Journal of community health · 2021Article
- Healthcare Providers' Vaccine Perceptions, Hesitancy, and Recommendation to Patients: A Systematic Review.Vaccines · 2021Review
- Suboptimal uptake of meningococcal vaccines among older adolescents: Barriers, solutions, and future research directions.Human vaccines & immunotherapeutics · 2020Article
- Variability in influenza vaccination opportunities and coverage among privately insured children.Vaccine · 2020Article
- Parental awareness and utilization of meningococcal serogroup B vaccines in the United States.BMC public health · 2020Article
- Disparities in healthcare providers' interpretations and implementations of ACIP's meningococcal vaccine recommendations.Human vaccines & immunotherapeutics · 2020Article
- HPV Vaccine Delivery Practices by Primary Care Physicians.Pediatrics · 2019Article
- Parental awareness of Meningococcal B vaccines and willingness to vaccinate their teens.Vaccine · 2019Article
- A physician's guide to the 2-dose schedule of MenB-FHbp vaccine.Human vaccines & immunotherapeutics · 2019Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
: media-1vid110.1542/5799875076001PEDS-VA_2018-0344
methodsWe surveyed a nationally representative sample of pediatricians and FPs via e-mail and Internet from October 2016 to December 2016.
resultsThe response rate was 72% (660 of 916). During routine visits, 51% of pediatricians and 31% of FPs reported always or often discussing MenB vaccine. Among those who discussed often or always, 91% recommended vaccination; among those who never or rarely discussed, 11% recommended. We found that 73% of pediatricians and 41% of FPs currently administered the MenB vaccine. Although many providers reported not knowing about factors influencing recommendation decisions, MenB disease outbreaks (89%), disease incidence (62%), and effectiveness (52%), safety (48%), and duration of protection of MenB vaccine (39%) increased the likelihood of recommendation, whereas the Category B recommendation (45%) decreased likelihood. Those somewhat or not at all aware of the MenB vaccine (risk ratio 0.32 [95% confidence interval 0.25-0.41]) and those practicing in a health maintenance organization (0.39 [0.18-0.87]) were less likely, whereas those aware of disease outbreaks in their state (1.25 [1.08-1.45]) were more likely to discuss MenB vaccine.
conclusionsPrimary care physicians have significant gaps in knowledge about MenB disease and the MenB vaccine, and this appears to be a major driver of the decision not to discuss the vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.